Ghost Tree Capital’s Neurocrine Biosciences NBIX Stock Holding History

Ghost Tree Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-225,000	Closed	-$13.8M	–	62
2017 Q3	$13.8M	Buy	225,000 +75,000	+50%	+$3.96M	2.93%	9
2017 Q2	$6.9M	Sell	150,000 -150,000	-50%	-$7.28M	1.43%	27
2017 Q1	$13M	Buy	+300,000	New	+$12.9M	2.42%	6
2016 Q3	–	Sell	-125,000	Closed	-$5.68M	–	94
2016 Q2	$5.68M	Buy	+125,000	New	+$5.75M	1.64%	23
2015 Q4	–	Sell	-55,000	Closed	-$2.19M	–	65
2015 Q3	$2.19M	Sell	55,000 -67,500	-55%	-$3.26M	0.98%	40
2015 Q2	$5.85M	Buy	+122,500	New	+$5.19M	1.9%	20
2014 Q4	–	Sell	-100,000	Closed	-$1.57M	–	80
2014 Q3	$1.57M	Buy	+100,000	New	+$1.49M	0.85%	46

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ghost Tree Capital's NBIX Position: Q4 2017 in Review

Ghost Tree Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2017, closing a stake of 225,000 shares — an estimated $13.8M sold.

Ghost Tree Capital first reported a position in NBIX in Q3 2014 and held it in 7 quarters. The position peaked at $13.8M in Q3 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

Ghost Tree Capital reported no remaining Neurocrine Biosciences position as of Q4 2017 after selling out during the quarter.
Ghost Tree Capital sold 225,000 Neurocrine Biosciences shares in Q4 2017, an estimated $13.8M.
Ghost Tree Capital first reported a position in Neurocrine Biosciences in Q3 2014 and held it in 7 quarters.
Ghost Tree Capital's Neurocrine Biosciences position peaked at $13.8M in Q3 2017.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on Ghost Tree Capital's 13F filing for Q4 2017, filed 14 Feb 2018.